309 related articles for article (PubMed ID: 30715616)
1. BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer.
Genta S; Pirosa MC; Stathis A
Curr Oncol Rep; 2019 Feb; 21(2):13. PubMed ID: 30715616
[TBL] [Abstract][Full Text] [Related]
2. Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors.
Li C; Wang Y; Gong Y; Zhang T; Huang J; Tan Z; Xue L
Clin Epigenetics; 2021 Mar; 13(1):62. PubMed ID: 33761979
[TBL] [Abstract][Full Text] [Related]
3. Enhancer of zeste homolog 2 (EZH2) inhibitors.
Gulati N; Béguelin W; Giulino-Roth L
Leuk Lymphoma; 2018 Jul; 59(7):1574-1585. PubMed ID: 29473431
[TBL] [Abstract][Full Text] [Related]
4. BET inhibitors: a novel epigenetic approach.
Doroshow DB; Eder JP; LoRusso PM
Ann Oncol; 2017 Aug; 28(8):1776-1787. PubMed ID: 28838216
[TBL] [Abstract][Full Text] [Related]
5. Tazemetostat for the treatment of multiple types of hematological malignancies and solid tumors.
Marsh S; Jimeno A
Drugs Today (Barc); 2020 Jun; 56(6):377-387. PubMed ID: 32525136
[TBL] [Abstract][Full Text] [Related]
6. Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs.
Gelato KA; Adler D; Ocker M; Haendler B
Expert Opin Ther Targets; 2016 Jul; 20(7):783-99. PubMed ID: 26799480
[TBL] [Abstract][Full Text] [Related]
7. BET Proteins as Attractive Targets for Cancer Therapeutics.
Sarnik J; Popławski T; Tokarz P
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681760
[TBL] [Abstract][Full Text] [Related]
8. Role of the EZH2 histone methyltransferase as a therapeutic target in cancer.
Italiano A
Pharmacol Ther; 2016 Sep; 165():26-31. PubMed ID: 27179746
[TBL] [Abstract][Full Text] [Related]
9. Targeting EZH2 as cancer therapy.
Hanaki S; Shimada M
J Biochem; 2021 Sep; 170(1):1-4. PubMed ID: 33479735
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.
Bernasconi E; Gaudio E; Lejeune P; Tarantelli C; Cascione L; Kwee I; Spriano F; Rinaldi A; Mensah AA; Chung E; Stathis A; Siegel S; Schmees N; Ocker M; Zucca E; Haendler B; Bertoni F
Br J Haematol; 2017 Sep; 178(6):936-948. PubMed ID: 28653353
[TBL] [Abstract][Full Text] [Related]
11. BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes.
Zaiken MC; Flynn R; Paz KG; Rhee SY; Jin S; Mohamed FA; Saha A; Thangavelu G; Park PMC; Hemming ML; Sage PT; Sharpe AH; DuPage M; Bluestone JA; Panoskaltsis-Mortari A; Cutler CS; Koreth J; Antin JH; Soiffer RJ; Ritz J; Luznik L; Maillard I; Hill GR; MacDonald KPA; Munn DH; Serody JS; Murphy WJ; Kean LS; Zhang Y; Bradner JE; Qi J; Blazar BR
Blood; 2022 May; 139(19):2983-2997. PubMed ID: 35226736
[TBL] [Abstract][Full Text] [Related]
12. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.
Morera L; Lübbert M; Jung M
Clin Epigenetics; 2016; 8():57. PubMed ID: 27222667
[TBL] [Abstract][Full Text] [Related]
13. Developing EZH2-Targeted Therapy for Lung Cancer.
Frankel AE; Liu X; Minna JD
Cancer Discov; 2016 Sep; 6(9):949-52. PubMed ID: 27587466
[TBL] [Abstract][Full Text] [Related]
14. Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors.
Ramadoss M; Mahadevan V
Drug Discov Today; 2018 Jan; 23(1):76-89. PubMed ID: 28943305
[TBL] [Abstract][Full Text] [Related]
15. Targeting EZH2 in cancer therapy.
Yamagishi M; Uchimaru K
Curr Opin Oncol; 2017 Sep; 29(5):375-381. PubMed ID: 28665819
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.
Christofides A; Karantanos T; Bardhan K; Boussiotis VA
Oncotarget; 2016 Dec; 7(51):85624-85640. PubMed ID: 27793053
[TBL] [Abstract][Full Text] [Related]
17. Targeting BET bromodomain proteins in solid tumors.
Sahai V; Redig AJ; Collier KA; Eckerdt FD; Munshi HG
Oncotarget; 2016 Aug; 7(33):53997-54009. PubMed ID: 27283767
[TBL] [Abstract][Full Text] [Related]
18. Anticancer drugs: All roads lead to EZH2 inhibition.
Villanueva MT
Nat Rev Drug Discov; 2017 Mar; 16(4):239. PubMed ID: 28356595
[No Abstract] [Full Text] [Related]
19. Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors.
Huang X; Yan J; Zhang M; Wang Y; Chen Y; Fu X; Wei R; Zheng XL; Liu Z; Zhang X; Yang H; Hao B; Shen YY; Su Y; Cong X; Huang M; Tan M; Ding J; Geng M
Cell; 2018 Sep; 175(1):186-199.e19. PubMed ID: 30220457
[TBL] [Abstract][Full Text] [Related]
20. Design, Synthesis, and Biological Evaluation of a Potent Dual EZH2-BRD4 Inhibitor for the Treatment of Some Solid Tumors.
Huang N; Liao P; Zuo Y; Zhang L; Jiang R
J Med Chem; 2023 Feb; 66(4):2646-2662. PubMed ID: 36774555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
